8V8.F GENETIC ANALYSIS NK -60
- Market cap
- EUR 2.34M
- P/E
- -
- P/B
- 1.18x
- ROE
- -68.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8V8.F undervalued?
Graham numberThe Graham number of GENETIC ANALYSIS NK -60 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GENETIC ANALYSIS NK -60 fundamental analysis
No fundamental analysis for GENETIC ANALYSIS NK -60 yet.
GENETIC ANALYSIS NK -60 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome resear…
Full company profileGENETIC ANALYSIS NK -60 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GENETIC ANALYSIS NK -60 annual financial statements (NOK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 6.80M | 11.2M | 14.1M | 15.9M | 16.7M | 7.70M |
| Gross Profit | 5.52M | 7.26M | 9.72M | 12.8M | 12.0M | 4.70M |
| Operating Income | -28.9M | -28.2M | -23.2M | -13.7M | -10.4M | -23.5M |
| EBITDA | - | -23.3M | -18.0M | -9.17M | -5.74M | -6.92M |
| Net Income | -29.0M | -28.3M | -23.8M | -14.8M | -11.4M | -14.1M |
| EPS | -1.11 | -1.08 | -0.60 | -0.29 | -0.17 | -0.20 |
| Balance Sheet | ||||||
| Total Assets | 83.5M | 64.4M | 53.5M | 42.4M | 52.4M | 44.6M |
| Total Liabilities | 11.4M | 20.3M | 21.5M | 19.9M | 25.4M | 23.9M |
| Shareholders' Equity | 72.1M | 44.1M | 32.0M | 22.5M | 27.1M | 20.7M |
| Cash & Short-term Investments | 46.0M | 24.4M | 15.3M | 12.8M | 23.4M | 14.5M |
| Cash Flow | ||||||
| Operating Cash Flow | -27.6M | -19.5M | -17.2M | -11.6M | 2.40M | -19.1M |
| Capital Expenditure | 1.95M | 227K | 643K | 1.95M | 5.54M | 5.37M |
| Free Cash Flow | -29.6M | -19.7M | -17.9M | -13.6M | -3.13M | -24.4M |
| Ratios | ||||||
| ROE | -40.2% | -64.1% | -74.4% | -65.7% | -42.1% | -68.0% |
| ROA | -34.7% | -43.9% | -44.5% | -34.9% | -21.8% | -31.6% |
| Net Profit Margin | -426.6% | -253.3% | -168.4% | -93.0% | -68.3% | -183.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GENETIC ANALYSIS NK -60 dividends
GENETIC ANALYSIS NK -60 has not paid dividends in the last 5 fiscal years.
Who owns GENETIC ANALYSIS NK -60
- Insiders 61.75%
- Institutions 9.87%
- Public & others 28.38%
- Shares outstanding 69.1M
- Free float 19.5M
GENETIC ANALYSIS NK -60 company profile
- Company name
- GENETIC ANALYSIS NK -60
- Ticker
- 8V8.F
- ISIN
- NO0010692130
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 18
- Fiscal year end
- December
- Address
- Ulvenveien 80B, Oslo, Norway, 0581
- Phone
- 47 48 32 16 10
- Website
- genetic-analysis.com
About GENETIC ANALYSIS NK -60
Genetic Analysis AS, a science-based diagnostic company, engages in the research, development, manufacturing, and sale of diagnostic test solutions for human microbiome in the United States, Europe, and internationally. The company offers GA-map MHI Gut Health Test, a microbiome-based diagnostic test for antibiotic-induced microbiome imbalances; GA-map Dysbiosis Test, a diagnostic microbiome test that detects and characterizes dysbiosis; GA-map Discovery, a microbiome research assay; GA-map Sample Collection Kit for the collection, transport, and storage of fecal specimens for nucleic acid analysis; GA-map IBD Precision Dx, a biomarker for inflammatory bowel disease; and GA-map COVID-19 Fecal Test, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples. It is also involved in the operation of service laboratory where customers can send samples for microbiome profiling analysis; and provision of bioinformatic analysis and custom panel services. The company was founded in 2008 and is headquartered in Oslo, Norway.
GENETIC ANALYSIS NK -60 management
5- Mr. Ronny Hermansen MScChief Executive Officer · born 1963
- Mr. Lars TillerHead of Operations
- Ms. Christina CasenSenior Vice President of Clinical & Medical Affairs
- Ms. Kari FuruHead of Commercial
- Ms. Mira Halvorsen BørstadChief Commercial Officer